CRPS is one of the worst pain syndromes and no drug has ever been approved by any regulatory agency for the treatment of people suffering from this often debilitating disease.
The granting of the Orphan Designation supports the quality of our pre-clinical and not at least clinical data to treat patients suffering from Complex Regional Pain Syndrom (CRPS) and neuropathic pain in general.
The Orphan designation also reinforces the AKIGAI strategy to start a possibly pivotal phase II/III trial for CRPS patients in 2025 with the aim of approval for CRPS in 2027.